LISINOPRIL 2.5MG tablet

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

LISINOPRIL (UNII: E7199S1YWR) (LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)

Available from:

Mckesson Contract Packaging

INN (International Name):

LISINOPRIL

Composition:

LISINOPRIL 2.5 mg

Prescription type:

PRESCRIPTION DRUG

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

LISINOPRIL 2.5MG- LISINOPRIL TABLET
LISINOPRIL 5MG- LISINOPRIL TABLET
LISINOPRIL 10MG- LISINOPRIL TABLET
LISINOPRIL 20MG- LISINOPRIL TABLET
LISINOPRIL 40MG- LISINOPRIL TABLET
MCKESSON CONTRACT PACKAGING
----------
LISINOPRIL TABLETS USP
RX ONLY
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
•
•
DESCRIPTION
Lisinopril is an oral long-acting angiotensin converting enzyme
inhibitor. Lisinopril, a synthetic peptide
derivative, is chemically described as (S)-1-[N2-(1-carboxy-3-
phenylpropyl)-L-lysyl]-L-proline
dihydrate. Its empirical formula is C
H N O • 2H O and its structural formula is:
Lisinopril is a white to off-white, crystalline powder, with a
molecular weight of 441.53. It is soluble
in water and sparingly soluble in methanol and practically insoluble
in ethanol.
Lisinopril tablets USP is supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30
mg and 40 mg tablets for oral
administration.
Inactive Ingredients:
Lisinopril 2.5 mg tablets – calcium phosphate, magnesium stearate,
mannitol, corn starch.
Lisinopril 5 mg, 10 mg and 30 mg tablets – calcium phosphate,
magnesium stearate, mannitol, red iron
oxide, corn starch.
Lisinopril 20 mg tablets – calcium phosphate, magnesium stearate,
mannitol, red iron oxide, corn starch,
yellow iron oxide.
Lisinopril 40 mg tablets – calcium phosphate, magnesium stearate,
mannitol, corn starch, yellow iron
oxide.
CLINICAL PHARMACOLOGY
• WHEN PREGNANCY IS DETECTED, DISCONTINUE LISINOPRIL AS SOON AS
POSSIBLE.
• DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH TO
THE DEVELOPING FETUS. SEE WARNINGS, FETAL TOXICITY.
21
31
3
5
2
MECHANISM OF ACTION
Lisinopril inhibits angiotensin-converting enzyme (ACE) in human
subjects and animals. ACE is a
peptidyl dipeptidase that catalyzes the conversion of angiotensin I to
the vasoconstrictor substance,
angiotensin II. Angiotensin II also stimulates aldosterone secretion
by the adrenal cortex. The beneficial
effects of lisinopril in hypertension and heart failure ap